Rheumatoid Arthritis
XRay Bone Erosions in CCP+ Patients: Dr Eric Dein
Dr. Eric Dein discusses abstract #0760 presented at the 2020 ACR annual meeting.
Dr. Antoni Chan synovialjoints
4 years 11 months ago
Etanercept monotherapy significantly more effective than Methotrexate monotherapy in maintaining remission in RA patients on combination therapy. Data from the SEAM-RA study @RheumNow #ACR20 Abstr#0939 #ACRbest
Combo Therapy v Monotherapy (SEAM-RA Trial): Dr. Richard Conway
Dr. Conway discusses ACR abstract #0939 presented Saturday at the 2020 ACR annual meeting.
What is the SEAMless transition from combination Etanercept to Methotrexate? Dr. Jonathan Kay
Dr. Jonathan Kay takes a deep dive into plenary abstract #0939 presented at the ACR 2020 annual meeting, reviewing two previous clinical trials that also looked at this question and offering his perspective.
Staying on Therapy in RA: Dr. Janet Pope
Dr. Janet Pope reviews abstract #0804 - Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands- presented at the ACR 2020 annual meeting.
Dr. John Cush RheumNow
4 years 11 months ago
Rheumatoid arthritis and lung disease in the spotlight at #ACR20 by @jeffsparks
https://t.co/0Dth0k6uve https://t.co/pGfGtq8Sz7
Combination therapy with biologic and conventional DMARDs can be highly effective at inducing remission in patients with RA. Once controlled, patients are often interested in stopping combination drug therapy due to concerns related to medication burdens, side effect profiles, or safety.
Richard Conway RichardPAConway
4 years 11 months ago
After the SEAM-RA study, in patients taking MTX and ETN in sustained remission would you? #ACR20 @rheumnow
k dao KDAO2011
4 years 11 months ago
We have great options all around! Both are efficacious in biologic (TNFi) failures for RA patients.
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis Abst#0827 #ACR20 @RheumNow
https://t.co/1SsL9qLJD3
k dao KDAO2011
4 years 11 months ago
When you counsel patients w/RA, do you warn them that during times of dz flare, their ability to drive may be affected? ...maybe you should based on Abstr#0198
#ACR20 @rheumnow
David Liew drdavidliew
4 years 11 months ago
Nice insights into RA-ILD from @jeffsparks:
- assoc (in Medicare): male, smoker, asthma/COPD, b/tsDMARDs, steroids
- mortality risk? Yes, esp resp (sdHR 4.4), cancer
- ACPA/lung inflamm related to RA-ILD? Yes, esp anti-filaggrin (aOR 3.08/log unit)
#ACR20 ABST0489/0490 @RheumNow https://t.co/DGkNNPOcbd
Improving Drug Adherence in RA: Dr. Janet Pope
Dr. Janet Pope reviews abstract #0799 presented Saturday at the ACR 2020 annual meeting.
SEAM-RA Trial: Dr. Jeff Curtis
Dr. Jeff Curtis discusses abstract #0939, which looked at whether RA patients at or close to remission should continue taking their combination therapy, as presented at ACR 2020.
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 11 months ago
Be sure to check this session with @CCalabreseDO and Dr. Gordon Lam on the role of IL6 in inflammation, RA, and CRS at 2 pm EST today! #ACR20 @RheumNow https://t.co/c4oX1tNeId
Janet Pope Janetbirdope
4 years 11 months ago
Is it time to change RA EULAR guidelines to reflect what we do? SEAM RCT showed withdrawal of MTX better than D/C etanercept in controlled RA. ETN alone =ETN+MTX. I vote to d/c the Rx that failed or by pt preference! Abstr#939 @RheumNow #ACR20 https://t.co/l9TNM3Gt0e
Poster Hall